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CASE REPORT
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ABSTRACT
Ischaemic skin ulcer occurred on the foot of a 73-year-old man who had a history of fulminant
myocarditis with severe cardiac dysfunction. We attempted wound bed preparation by maggot
debridement therapy and salvaged his limb. It can be one of the adjuvant treatment strategies
for critical limb ischaemia.
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Introduction
Maggot therapy is categorised as a debridement for
chronic infectious wounds using disinfected live mag-
gots for medical use (herein referred to as maggots).
Since the 1930s, maggot debridement therapy (MDT)
has been conducted mainly in North America [1]. In
Japan, Mitsui et al. first conducted MDT in 2004 and
reported the healing of an ulcerated lesion, leading to
the avoidance of major amputation of a limb of a
patient with severe CLI for whom neither a revasculari-
zation procedure nor a transplantation of bone mar-
row and peripheral mononuclear cells to the lower
limb was effective [2].
Wound healing is intractable in most CLI patients
who have reduced blood flow in the skin; therefore,
revascularization is the most important factor for suc-
cessful management [3]. In addition, the debridement
of wounds with no sufficient tissue blood flow may
deteriorate ischaemic lesions. Therefore, MDT has been
relatively contraindicated for ischaemic limbs [4,5].
Treatment decisions are often difficult for CLI
patients with a reduced cardiac function and surgical
intervention or endovascular surgery for revasculariza-
tion is risky, or not clinically and technically possible [6].
Herein, we report a CLI patient with severe cardiac
dysfunction for whom highly invasive surgery, such as
bypass surgery, was impossible due to a history of ful-
minant myocarditis, but functional limb salvage was
achieved after wound bed preparation (WBP) with
MDT.
Case report
A 73-year-old man consulted our institution for a skin
ulcer of the left third toe in September 2014. He had a
clinical history of fulminant myocarditis, myocardial
infarction, acute cardiac failure, chronic renal failure
(undergoing dialysis), arteriosclerosis obliterans of the
lower limb, hypertension, diabetes and visual disturb-
ance. He was a non-smoker, living by himself, and he
could walk with support.
His notable illness was an episode of fulminant
myocarditis and acute cardiac failure in December
2011, which was treated in the ICU for 15 days, and
he was discharged from hospital 3 months later. At
the time of discharge, he still had significant cardiac
functional disorder with an ejection fraction (EF) rate
of less than 20%.
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In April 2014, he developed ulceration of the right
toes, diagnosed as arteriosclerosis obliterans of the
lower limb at the cardiovascular medicine department
and underwent percutaneous transluminal angioplasty
(PTA). In September 2014, delayed healing of the
ulceration of the skin was noted; thus, he was referred
to the plastic surgery department.
Upon the first consultation at the plastic surgery
department, ischaemic ulcer of the left third toe was
seen and his EF rate was 18.4%. Table 1 shows his bio-
logic and haematologic data, detected bacteria and
treatment course. Biological data on the left limb were
examined between the revascularization procedure
and surgical management, and blood test and wound
culture were examined at the time of surgical manage-
ment. Revascularization procedure by PTA was not
conducted after October 2016.
In September 2014, after performing PTA for the
left lower limb, amputation of the left third toe was
conducted. In December 2014, re-stenosis of the bilat-
eral below-knee arteries and necrosis of the left first
toe were noted, thus re-PTA was conducted for the
bilateral limbs. Subsequently, amputation of the left
first toe was performed. In September 2015, arterial re-
stenosis of the lower extremity developed along with
necrosis of all the left toes, plantar and dorsum, and
so PTA was performed again; transmetatarsal amputa-
tion (TMA) was also performed in the same month.
However, delayed wound healing, infection and necro-
sis progressed in the transected surface of the left
limb. Therefore, in January 2016, the first and second
toes were amputated at Lisfranc’s joint, and the other
three toes were further amputated at the base of the
transmetatarsal bone, and the amputated surface was
left as an open wound for WBP and post-operative
infection management. At the time of the amputation,
extensive arterial contraction and severe arterioscler-
osis were noted in the left lower limb; thus, an add-
itional revascularization procedure by PTA could not
be performed. Subsequently, cleansing of the wound,
topical ointment of sulfadiazine silver, venous drip
infusion of an antibiotic agent (daptomycin), and sur-
gical debridement at the bedside were conducted
daily, but the yellowish necrosis lesion did not reduce,
and his pain aggravated (Figure 1(a)).
The patient strongly desired to save his limb and
refused to undergo major amputation of the limb.
Debridement at the bedside was difficult due to pain
at that time. Surgical management under general
anaesthesia (such as bypass surgery) or extensive and
highly invasive debridement for a long time was also
considered unacceptable, because the patient fulfilled
three items of the Revised Cardiac Risk Index (history Ta
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of cardiac failure, insulin-dependent diabetes and renal
failure), had EF of 18.4% and had a constantly high
level of B-type natriuretic peptide (over 2000 pg/mL).
As conventional treatment methods were considered
difficult for the patient to tolerate, MDT was started
from February 2016. The Barthel Index [7] before MDT
was a score of 45.
Second instar larvae of maggots were placed on
the surface of the skin ulcer at six larvae per 1 cm2,
covered by a mesh sheet and dressing was performed.
The maggots were removed when they grew to third
instar larvae and were replaced by second instar lar-
vae. By defining a 48-h duration as one session, a total
of six sessions were conducted. For pain control, the
oral administration of NSAIDs was performed and he
could tolerate the pain, although it remained to a cer-
tain extent. Subsequently, compared with the conven-
tional treatment, the reduction of necrotic tissues at
the ulceration site was noted each time the maggots
were replaced, and favourable granulation was
observed. MDT was particularly effective in the portion
where the margin between the granulation and necrosis
was unclear, and the deep portion of the ulceration
where manual debridement was difficult (Figure 1(b–d)).
Wound closure was achieved in March 2016.
Intraoperative and post-operative views are shown
in Figure 2(a,b). Under sciatic nerve block, additional
debridement and partial simple reefing suture were
done, and skin graft with a split thickness of 20/1000
inches was conducted, harvesting the graft from his
left inguinal region. The operation took 1 h and
40min, and the amount of bleeding was 140mL.
Post-operatively, about 70% of the grafted skin was
taken, although it was unstable for 2 weeks, and his
pre-operative pain markedly reduced. Although some
raw surface remained, the range was relatively small,
Figure 1. Treatment course of maggot therapy. (a) Before maggot therapy. Necrotic tissue is seen on the surface of the wound.
(b) After one session (48 h) of treatment, the reduction of necrotic tissues is seen. (c) Maggots growing from second to third instar
larvae. (d) After six sessions of treatment, debridement was conducted to the deep portion from the ulcerated base, and favour-
able granulation can be seen on the amputated surface.
Figure 2. Intra-/post-operative view. (a) Intra-operative. Additional debridement is done. (b) Three post-operative weeks.
Approximately 70% of the skin graft was taken. After conducting partial simple reefing, split thickness skin graft of 20/1000 inches
was used.
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and additional surgical management was unnecessary.
After rehabilitation exercise, as of one post-operative
months, he became able to stand with assistance
when moving from a wheelchair, walk using a four-
point walker, and his Barthel Index improved to a
score of 80 (Figure 3(b)).
Discussion
In patients with CLI, debridement may deteriorate
necrosis by inducing ischaemia of normal tissues.
Therefore, blood flow evaluation and the revasculariza-
tion procedure are important before conducting
debridement. However, clinically or technically, up to
(maximum) 14% of CLI patients are unable to undergo
surgical management or endovascular surgery for
angioplasty [6]. Also, Soga et al. reported a vascular re-
stenosis rate of 86.0% and re-occlusion rate of 52.8%
in CLI patients who underwent endovascular manage-
ment [8]. In our patient, although the preoperative
Ankle Brachial Index and skin perfusion pressure were
relatively maintained, arterial restenosis of the lower
extremity was seen before healing, and PTA was con-
ducted three times. In addition, vascular reconstruction
by additional PTA was difficult after October 2016.
Some CLI patients are unable to undergo highly
invasive surgery because of a reduced cardiac func-
tion. Shiraki et al. reported that 15.6% of their CLI
patients had an EF rate of less than 50% and 41.1%
had coronary artery disease (CAD) [9]. In addition, a
mortality rate of less than 25% has been reported
within a year for CLI patients [10]. Physiologic classifi-
cation of the American Society of Anesthesiologists
(ASA) reports perioperative mortality rate of class-III
patients (angina, old myocardial infarction, and insulin-
dependent diabetes) and class-IV patients (unstable
angina) of 1.8% and 7.8%, respectively [11]. The
Revised Cardiac Risk Index, which is commonly used
to predict cardiovascular events during a perioperative
period, defines six risk factors: ischaemic cardiac dis-
ease, history of cardiac failure, cerebrovascular disease,
insulin-dependent diabetes, renal failure and high-risk
surgical management [12]. If a patient has three or
more of these risk factors, when conducting non-car-
diac surgery, the average cardiovascular complication
rate is reported to be 9.1% and mortality due to car-
diovascular disease is 3.6% [12,13]. Our patient had
three of these risk factors, suggesting a high risk dur-
ing the perioperative period.
Adjuvant therapies for ischaemic ulcer, other than
MDT, include hyperbaric oxygen therapy [14], cell ther-
apy [15], gene therapy (intravascular growth factor)
[16] and LDL apheresis [17]. However, these therapies
require special equipment and qualification as a spe-
cialist; thus, they are difficult to perform flexibly
depending on the needs of a particular situation. On
the other hand, MDT can be conducted less problem-
atically in ordinary hospitals or outpatient clinics,
although it is categorised as a private practice in
Japan and thus not covered by the Japanese national
health insurance system [18].
Four debridement methods are considered for the
selective removal of necrotic tissues: (1) surgical debride-
ment, (2) enzymatic debridement, (3) autolytic
debridement and (4) biological debridement. Surgical
debridement removes necrotic tissues with scissors or
Figure 3. Treatment outcome at one post-operative months. The Barthel Index improved from a score of 45 to 80, and the
patient started to walk using a four-point walker.
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a scalpel, which entails bleeding and pain of patients,
as well as damage to peripheral intact tissues to some
extent. Enzymatic debridement uses chemical agents
for liquefaction of necrotic tissues and is also called
chemical debridement. This can be done without
anaesthesia and is relatively simple to perform with lit-
tle risk of bleeding; however, it is a time-consuming
procedure and thus not suitable for situations requir-
ing more immediate results. Autolytic debridement
involves the application of wound dressing materials
such as ointments or hydrocolloid materials, making it
suitable for wounds that locate near the body surface
or autonomic healing power of the wound is
maintained.
There are three major benefits of WBP by MDT for
CLI patients [19–21]. First, selective and efficient
debridement can be performed. Even for wounds with
unclear margins with the surrounding normal tissues,
maggots selectively englobe and liquefy only necrotic
tissues [22]. In addition, as maggots naturally favour
darker environments (negative phototaxis), maggots
reach to the deep portions of a wound where surgical
debridement is difficult. Pain associated with MDT can
be controlled with oral analgesics or by controlling the
number of applied maggots, making local or surface
anaesthesia unnecessary [23]. Further, the technique
for MDT is relatively straightforward and easily learned,
so a certain efficacy can be obtained irrespective of
the proficiency of each surgeon. Even for patients of
advanced age, with dementia, or unfavourable sys-
temic conditions, for whom surgical debridement is
problematic, MDT can be utilised.
A second benefit is the antibacterial action associ-
ated with MDT. Maggots have a sterilising effect both
in vivo and in vitro. In the body, maggots eliminate
bacteria through a digesting process in their foregut,
midgut and hindgut [24]. In an extracorporeal (in vitro)
study, antibacterial peptide contained in maggots’
secretion was shown to be effective against Gram-
positive bacterium, including Methicillin-resistant
Staphylococcus aureus (MRSA) [25]. Thus, MDT is con-
sidered suitable for CLI patients who likely face the
presence of multiple drug-resistant bacteria at high
incidence, because of relative immune deficiency and
long-term hospitalisation. Harmful bacteria including
MRSA were not detected in wound cultures of our
patient in the months of January and February 2016,
while MDT was being conducted, suggesting effective
antibacterial action of the maggots’ secretions.
A third benefit is a promotion of granulation forma-
tion with MDT. Maggot secretions promote the cellular
processes, which is related to increased healing activ-
ity. Such processes include activation of fibroblast
migration, angiogenesis (the formation of new blood
vessels from pre-existing vessels) within the wound
bed and an enhanced production of growth factors
within the wound environment [19,20]. These are
believed to have been part of the success of WBP with
our patient although his skin perfusion pressure (SPP)
in the dorsum of the foot was only 15mmHg before
MDT. A recent case report also indicated the possibility
of MDT to improve blood flow, in addition to support-
ing its effectiveness for debridement, showing the
increased skin perfusion pressure by 42mmHg in the
dorsum and 27mmHg in the plantar [26].
Nevertheless, the number of published articles on this
aspect is limited, and thus further investigation will be
necessary before clear determination can be made.
Our case presented with five problematic condi-
tions: (1) delayed WBP due to circulation failure, (2)
difficulty of angioplasty after re-stenosis, (3) contraindi-
cation of highly invasive treatment, (4) infection by
MRSA and (5) pain. To cope with these difficulties,
MDT provided the benefits of the following: (1) cap-
ability of WBP by removing necrotic tissues with
unclear margins, (2) possibility of improving blood
flow, (3) effective debridement with low invasiveness,
(4) antibiotic effect on MRSA and (5) capability of pain
control using analgesics, adjusting the number of
maggots and duration of treatment. The Barthel Index
at the time of discharge from the hospital was a score
of 80; thus, we considered that functionally meaning-
ful limb salvage could be pursued.
From these facts, MDT is believed to be an effective
method to improve the wound surface with delayed
healing, under the condition that a certain revasculari-
zation procedure is performed. MDT is one of the
promising adjuvant treatments for patients with an
unfavourable systemic condition and difficulty in
undergoing highly invasive surgery.
Conclusions
In conclusion, we could achieve functionally meaningful
lower limb salvage by WBP with MDT for an ulcerated
lower limb lesion in a CLI patient who had a severe
cardiac disorder, delayed healing of the wound surface
and difficulty in undergoing a revascularization proced-
ure after arterial restenosis. MDT is considered one of
the adjuvant treatment strategies even for patients
with CLI, provided it is performed appropriately.
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